SITC Resource Library

On September 13, 2018, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Roy S. Herbst, MD, PhD – Yale Cancer Center
• Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Patrick Forde, MD – Johns Hopkins University
• Scott N. Gettinger, MD – Yale Cancer Center 

The webinar discussed:

• The role of immunotherapy for the treatment of NSCLC
• The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
• Unique disease cases that may require adaption of immunotherapy utilization
• How best to manage immune-related adverse events

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date.

Please note that the on-demand webinar is not available for continuing education credits.

#Biomarkers #LungCancers #PresentationSlides #ClinicalPracticeGuideline #SITC #AdverseEvents #Atezolizumab #Durvalumab #CombinationTherapy #ImmuneCheckpointInhibitors #Ipilimumab #Nivolumab #Pembrolizumab #Clinician #RegisteredNurse #Oncologist #Pharmacist #2018 #RecordedWebinar #NonSmallCellLungCancer